Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review

Compounds derived from biologic sources, or biologicals, are increasingly utilized as therapeutic agents in malignancy. Development of anti-cancer targeted therapies from biologics is increasingly being utilized. Cetuximab, a chimeric monoclonal antibody, is one such anti-cancer targeted therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoag, Jeffrey B, Azizi, Aimel, Doherty, Timothy J, Lu, Jason, Willis, Rudolph E, Lund, Mark E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2735734/
https://www.ncbi.nlm.nih.gov/pubmed/19682368
http://dx.doi.org/10.1186/1756-9966-28-113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2735734/
https://www.ncbi.nlm.nih.gov/pubmed/19682368
http://dx.doi.org/10.1186/1756-9966-28-113

Ejemplares similares